These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 27062695)
1. CD90 a potential cancer stem cell marker and a therapeutic target. Shaikh MV; Kala M; Nivsarkar M Cancer Biomark; 2016; 16(3):301-7. PubMed ID: 27062695 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497 [TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019 [TBL] [Abstract][Full Text] [Related]
4. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines. Shu X; Liu H; Pan Y; Sun L; Yu L; Sun L; Yang Z; Ran Y Mol Cell Biochem; 2019 Sep; 459(1-2):35-47. PubMed ID: 31073886 [TBL] [Abstract][Full Text] [Related]
5. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843 [TBL] [Abstract][Full Text] [Related]
6. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Yan X; Luo H; Zhou X; Zhu B; Wang Y; Bian X Oncol Rep; 2013 Dec; 30(6):2733-40. PubMed ID: 24101104 [TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. Chen WC; Hsu HP; Li CY; Yang YJ; Hung YH; Cho CY; Wang CY; Weng TY; Lai MD Int J Oncol; 2016 Nov; 49(5):1881-1889. PubMed ID: 27633757 [TBL] [Abstract][Full Text] [Related]
8. CD26 a cancer stem cell marker and therapeutic target. Davies S; Beckenkamp A; Buffon A Biomed Pharmacother; 2015 Apr; 71():135-8. PubMed ID: 25960228 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087 [TBL] [Abstract][Full Text] [Related]
10. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Shimamura M; Nagayama Y; Matsuse M; Yamashita S; Mitsutake N Endocr J; 2014; 61(5):481-90. PubMed ID: 24531915 [TBL] [Abstract][Full Text] [Related]
11. Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. Skowron MA; Niegisch G; Fritz G; Arent T; van Roermund JG; Romano A; Albers P; Schulz WA; Hoffmann MJ J Exp Clin Cancer Res; 2015 Nov; 34():144. PubMed ID: 26606927 [TBL] [Abstract][Full Text] [Related]
12. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Luo J; Wang P; Wang R; Wang J; Liu M; Xiong S; Li Y; Cheng B Oncotarget; 2016 Feb; 7(8):9525-37. PubMed ID: 26848615 [TBL] [Abstract][Full Text] [Related]
13. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907 [TBL] [Abstract][Full Text] [Related]
14. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739 [TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oktem G; Sercan O; Guven U; Uslu R; Uysal A; Goksel G; Ayla S; Bilir A Oncol Rep; 2014 Aug; 32(2):641-9. PubMed ID: 24927163 [TBL] [Abstract][Full Text] [Related]
16. Surface markers of hepatocellular cancer stem cells and their clinical potential. Feng D; Wang N; Hu J; Li W Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843 [TBL] [Abstract][Full Text] [Related]
17. Significance of CD90+ cancer stem cells in human liver cancer. Yang ZF; Ho DW; Ng MN; Lau CK; Yu WC; Ngai P; Chu PW; Lam CT; Poon RT; Fan ST Cancer Cell; 2008 Feb; 13(2):153-66. PubMed ID: 18242515 [TBL] [Abstract][Full Text] [Related]
18. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma. Zhu L; Zhang W; Wang J; Liu R Tumour Biol; 2015 Jul; 36(7):5353-60. PubMed ID: 25672610 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Lobba AR; Forni MF; Carreira AC; Sogayar MC Cytometry A; 2012 Dec; 81(12):1084-91. PubMed ID: 23090904 [TBL] [Abstract][Full Text] [Related]
20. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]